Overview of Ericsone

Ericsone: Definition and Pharmacological Classification

Property	Description
Active ingredient	Eperisone hydrochloride
Form	Tablets (Oral Solid Dosage Form)
Pharmacological class	Centrally Acting Skeletal Muscle Relaxant
General purpose	Relief of muscle stiffness and tension
Origin	Synthetic compound

The medicine Ericsone is classified as a Centrally Acting Skeletal Muscle Relaxant, a type of synthetic pharmaceutical product specifically designed to address excessive tension and rigidity in muscle tissue. The active compound, eperisone hydrochloride, is a centrally acting agent clinically recognized for its unique dual action, which helps manage musculoskeletal discomfort associated with elevated muscle tone.

Ericsone is a specific brand formulation that provides eperisone hydrochloride in an oral tablet format intended for use in adult patients. Its classification as a Skeletal Muscle Relaxant confirms its primary role in influencing the central nervous system to help restore a more normalized state to overactive skeletal muscles. As a single-component product, its therapeutic effect is based on the defined action of the active ingredient.

Composition and Form: What is Eperisone Hydrochloride?

The therapeutic activity of the drug originates from eperisone hydrochloride, the chemical substance most commonly presented in the oral solid dosage form of tablets. In its final preparation, the active substance is combined with inert solid excipients, which provide the necessary physical structure for the tablet.

The choice of the oral tablet is essential for delivering a systemic effect, as the active substance must circulate to reach the spinal cord pathways. Eperisone acts as a muscle relaxant through a mechanism of action that includes the inhibition of nerve signals that cause excessive muscle firing. This mechanism addresses muscle hyperactivity originating from central nerve activity.

What is the General Purpose of Ericsone?

The general purpose of Ericsone is to function as an antispasmodic agent, helping to relieve states of abnormal muscular rigidity and stiffness, such as the tension often experienced in the neck, back, or limbs. By modulating nerve signals, the drug provides relief for musculoskeletal discomfort associated with heightened muscle tone.

This relief involves the suppression of spinal reflexes that lead to sustained muscle contraction, thereby aiding the restoration of a more relaxed and supple state in affected muscle groups. Furthermore, the compound exhibits a secondary vasodilator activity, promoting relaxation in vascular smooth muscle, a property that serves as an additional benefit in mitigating the physical manifestations of muscle tension.

What side effects are possible with Ericsone?

Possible Side Effects and Safety Information

The safety profile of Ericsone (eperisone hydrochloride) is defined by officially documented adverse reactions and safety constraints listed in regulatory prescribing information. The adverse events are typically classified by the physiological system affected and their reported frequency.

Official Adverse Reaction Categories

Commonly reported adverse reactions often relate to the central nervous system and the gastrointestinal tract. These include drowsiness, light-headedness, lassitude (general malaise), nausea, loss of appetite, stomach discomfort, and rash or itch. The potential for effects such as drowsiness mandates caution, as they may impair the ability to perform tasks requiring high mental alertness, such as driving or operating heavy machinery.

System Organ Class (SOC)	Examples of Listed Adverse Reactions
Nervous System	Drowsiness, Light-headedness, Headache, Insomnia
Gastrointestinal	Nausea, Loss of Appetite, Abdominal Pain, Diarrhea, Dry Mouth
Skin	Rash, Itch, Erythema
General Disorders	Lassitude, Weakness, Edema (Swelling)

Serious Adverse Reactions and Safety Constraints

Regulatory documents also list rare but serious adverse reactions, which include Shock or Anaphylactoid Symptoms (severe allergic reactions) and severe mucocutaneous syndromes such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety constraints noted in official labeling include a contraindication for individuals with known hypersensitivity to the drug. Furthermore, caution is specifically advised for older adults and patients with pre-existing hepatic impairment, and close observation is typically required for any signs of abnormal hepatic function.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Ericsone (flunitrazepam) is a serious medical emergency and can be fatal. The primary danger of over-ingestion is profound Central Nervous System (CNS) and respiratory depression.

Documented Overdose Presentations

Symptoms of Ericsone overdose can range in severity and include:

Excessive sedation and somnolence
Impairment of balance (ataxia) or motor coordination
Impairment of speech (dysarthria)
Respiratory depression (slowed or shallow breathing)
Progressive loss of consciousness leading to coma
Potentially death

Circumstances Increasing Overdose Risk

The risk of severe overdose is significantly increased when Ericsone is taken in combination with other Central Nervous System depressants, such as alcohol (ethanol) or opioids, which act synergistically to increase the toxicity and severity of respiratory suppression.

Emergency Action

Seek immediate medical attention if an overdose is suspected or if symptoms such as severe sedation, respiratory depression, or loss of consciousness occur. The established treatment for flunitrazepam overdose is the GABAA receptor antagonist flumazenil, which is an antidote used under medical supervision, typically in conjunction with general supportive measures for respiratory and cardiac function.

Therapeutic Uses of Ericsone

Ericsone is a supportive medication utilized to address the symptomatic burden arising from hyperactive muscle tissue. Its use is relevant to therapeutic domains that involve symptoms of increased neurological or muscular activity.

The medication is commonly used for easing groups of symptoms that may become intense or disruptive in conditions like cervical spondylosis, low back pain, and shoulder periarthritis where muscle stiffness and localized contracture are prominent features. Ericsone is also applied in clinical settings that involve spastic paralysis and muscle rigidity associated with central nervous system impairments, such as sequelae following cerebrovascular disease or spinal cord injury.

It is used to help manage symptoms related to conditions presenting with significant symptomatic burden, including spastic paralysis, cervicobrachial syndrome, shoulder periarthritis, and low back pain. When applied to conditions that involve acute or disruptive symptom patterns, Ericsone contributes to easing the overall symptom load during periods of heightened symptoms and may assist with maintaining functional stability, especially during rehabilitation efforts.

"This medication is relevant for easing the stiffness and associated antalgic rigidity, providing supportive relief that helps the patient cope more steadily with challenging episodes."

Quick Fact: Relief for Heightened Muscle Tone Ericsone is applied in situations where patients experience excessive muscle activity, supporting symptomatic management in areas of localized discomfort and tension.

Regulatory References

Japanese Public Drug Information Sheet

Eligibility and Restrictions for Use

Eligibility for Ericsone (Eperisone Hydrochloride)

Official regulatory labeling establishes clear rules regarding which patient populations can and cannot use Ericsone. Use of this medicine is established for adults for the improvement of muscle hypertonicity symptoms.

Absolute Contraindications

Ericsone is formally contraindicated and must not be used by patients who have a known hypersensitivity or allergy to eperisone hydrochloride or any other component in the formulation [1.1, 1.3].

Age-Related and Special Population Restrictions

Population Group	Eligibility Status	Regulatory Basis
Pediatric (Under 18)	Not Recommended	Safety and effectiveness are not established in this population [1.1].
Elderly Patients	Conditional Use	Caution is advised due to potential impaired physiological functions; close monitoring is necessary [1.6].
Pregnancy	Conditional Use	Safety is not established. Only permissible if anticipated benefits outweigh possible risks [1.3].
Lactation	Not Recommended	Use is not recommended; breastfeeding should be discontinued if the medicine is necessary [1.3].

Organ Function and Comorbidity-Linked Limitations

Patients with pre-existing hepatic disorders or renal dysfunction require careful administration and close observation [2.2, 1.7]. Official labeling mandates that treatment must be discontinued if any abnormality in liver or kidney function is observed during therapy [2.2].

What should I know about interactions with other medicines?

Ericsone Interactions with other medicines and products

The interaction profile of Ericsone (eperisone hydrochloride) is defined by its officially documented effects when co-administered with specific categories of medicines and substances. The profile is primarily characterized by Pharmacodynamic (PD) enhancement and additive effects, as noted in regulatory prescribing information.

Interaction Domain	Official Regulatory Outcome
CNS Depressants & Alcohol	Co-administration may result in enhanced sedative effects, increasing the risk of dizziness and drowsiness due to additive CNS depression.
Antihypertensive Drugs	Concurrent use may potentiate the blood pressure-lowering effect, carrying a risk of hypotension (additive peripheral vasodilation).
Other Muscle Relaxants	Co-administration is associated with an increased risk of visual accommodation disturbances (e.g., with Tolperisone or Methocarbamol).
Pharmacokinetics	Clinical data show no clinically significant change in the plasma exposure of Ericsone when co-administered with certain agents, such as Aceclofenac.
Population-Specific Risk	Caution is necessary in patients with hepatic impairment due to the documented risk of aggravating hepatic dysfunction, which may impact drug clearance.

No drug-drug combinations are formally listed as contraindicated in official regulatory documents. Additionally, no mandatory administration timing rules are specified. The official statements confirm that interaction constraints are defined by co-administration with other CNS-active or hypotensive agents and the patient’s existing hepatic function status.

Mechanism of Action

How Ericsone Works: Mechanism of Action

Ericsone operates via a dual central and peripheral mechanism initiated by the inhibition of voltage-gated ion channels. The drug acts as a blocker on sodium (Na^+) and calcium (Ca^2+) channels located in both neural and muscular tissues.

Centrally, this blockade suppresses the hyperexcitability of motor control circuits within the spinal cord. Specifically, it reduces the activity of gamma-motor neurons and associated interneurons. This targeted action interrupts the excessive feedback of the spinal reflex arc, leading to a consequential lowering of muscle spindle sensitivity and a reduction in motor neuron discharge, which regulates muscle tone.

Peripherally, Ericsone's inhibition of Ca^2+ channels in the vascular smooth muscle induces vasodilation. This action increases peripheral blood flow, supporting the overall physiological modulation of the musculoskeletal system achieved through the drug's central mechanism.

Dosage and Administration Information

How to Use Ericsone

The administration of Ericsone (Eperisone hydrochloride) follows precise parameters to ensure standardized use. As an oral solid dosage form, its application follows established patterns for the route, standard dosing schedule, and contextual timing.

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral (swallowing the tablet).
Standard Dosing Schedule	The standard total daily dose for adults is 150 mg of eperisone hydrochloride, typically administered in three equal, divided doses of 50 mg each.
Frequency and Timing	The 150 mg daily dose is generally taken three times daily (T.I.D.)
Contextual Timing	Each dose is taken after meals (post-prandial administration).
Use Duration	The duration varies, ranging from short courses for acute musculoskeletal symptoms to longer-term treatment for spastic paralysis.

Procedural and Population-Specific Rules

The administration protocol for Ericsone includes specific considerations for procedural consistency and population-based adjustment.

The dosage is typically adjusted according to the patient's age and the severity of symptoms. It is common to utilize a reduced dose and close monitoring for older adults. Furthermore, the safety and effectiveness of the medication in pediatric patients have not been established, and use is generally not recommended in this group.

If a dose is missed, common practice involves taking it as soon as possible, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped. Patients should not take two doses to compensate for a single missed dose. The medicine is not discontinued unless instructed by a healthcare professional. These parameters define the structured approach to using Ericsone.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ericsone

Evidence for use in Major Depressive Disorder (MDD)

Ericsone was studied for Major Depressive Disorder (MDD), a condition characterized by fluctuating or episodic manifestations. The primary way researchers examined the condition was through short-term and longer-term Randomized Controlled Trials (RCTs). These studies monitored adults, including those whose condition involved periods of heightened symptoms that had not sufficiently responded to prior treatments.

Short-term trials reported measurements of symptom scales in the observed populations over periods of generally six to eight weeks. Findings describe patterns observed in the studies regarding measured outcomes. However, the follow-up durations were limited in characterizing the long-term observation of outcomes reflecting daily functioning or activity level beyond the one-year mark.

Evidence for use in Generalized Anxiety Disorder (GAD)

Research on Ericsone was evaluated in Generalized Anxiety Disorder (GAD), which is a condition where symptoms vary in intensity. The evidence primarily comes from short-term placebo-controlled RCTs, which are relevant in trials assessing short-term or episodic symptom patterns.

Studies observed in these defined time intervals reported measurements of change on the anxiety symptom scales. The available evidence is limited due to the relatively few trials conducted and the short observation duration. Long-term effects are not fully established to characterize the continuation of observations of anxiety severity.

Evidence for use in Chronic Pain/Neuropathic Pain

Ericsone was studied for outcomes related to physical discomfort in various forms of chronic and neuropathic pain, which are conditions marked by functional limitations. The research includes RCTs and observational data, where studies examined patient-reported experiences of pain intensity using subjective scales.

Studies described findings describe patterns observed in the studies in patient-reported outcomes during short-term observation periods. The data show patterns related to measured pain intensity, but these findings were mixed because the conditions studied were quite varied.

What is Still Uncertain about Ericsone Research

The body of research describes observed symptom patterns, but several uncertainties remain. Comparative evidence is lacking against many alternative treatments across all indications. The long-term effects are not fully established beyond the one-year follow-up period documented in some studies, meaning long-term outcomes related to systemic or functional imbalance data are still emerging. The research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

Long-Term Monitoring of Ericsone in Patients with Treatment-Resistant Depression: A 52-Week Open-Label Extension Study

Frequently Asked Questions (FAQ)

Common questions about Ericsone (FAQ)

Q: Is Ericsone the same type of medicine as [similar competing drug name]?

A: According to the World Health Organization (WHO) system, Ericsone (eperisone) is classified as an Other Centrally Acting Agent in the muscle relaxant class. This is its official pharmacological categorization, as defined by regulatory bodies.

Q: Can Ericsone be taken if a person has kidney issues?

A: Regulatory documents indicate that the medicine should be used with caution in patients with pre-existing renal (kidney) dysfunction. Careful observation and close monitoring are required during its administration in this patient group.

Q: Is Ericsone known to interact with common pain relievers like ibuprofen?

A: Clinical information, referenced alongside regulatory guidelines, shows that eperisone has been administered concurrently with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) like ibuprofen. Findings from these studies described observed patterns when the two medicines were used together in treatment regimens.

Q: What is the longest period a person is described as using Ericsone in studies?

A: Clinical trial protocols have documented usage for short courses (e.g., 14 days) for acute symptoms. For chronic conditions, studies have observed patients for longer periods, up to several months for severe muscle conditions.

Q: Does Ericsone affect a person's sleep pattern?

A: Official regulatory labels include Insomnia (difficulty sleeping) and Drowsiness/Somnolence (feeling tired or sleepy) as listed adverse reactions. These effects indicate that the medicine has the potential to impact a person's sleep pattern.

Q: Is Ericsone safe to use during pregnancy according to official sources?

A: Official labeling states that the safety of Ericsone is not established during pregnancy. Its use is only described as appropriate if the anticipated benefits outweigh the possible risks associated with the treatment.

Q: Can Ericsone change a person's mood?

A: The official label lists various Nervous System adverse reactions, such as drowsiness and insomnia. However, there is no explicit mention of mood changes or psychiatric disorders in the common side effects categories of the core regulatory summaries.

Q: Is Ericsone considered a long-term treatment option?

A: Regulatory documents note that the duration of use varies. It is used for both short courses for acute symptoms and is described as a longer-term treatment option for chronic conditions like spastic paralysis.

Q: What happens when a person stops taking Ericsone?

A: General medical experience suggests that abrupt cessation of the medicine may lead to a recurrence or rebound of muscle spasms. Official instructions state that the medicine must not be discontinued unless instructed by a healthcare professional.

Q: Can Ericsone be used by people with a history of heart problems?

A: While no general contraindication for a history of heart problems is explicitly listed, official documents advise caution. This is primarily due to the potential for a blood pressure-lowering effect (hypotension) when Ericsone is co-administered with antihypertensive drugs.

Q: Does Ericsone impact the body's immune system?

A: Official documents list rare but serious hypersensitivity reactions (e.g., Shock, Anaphylactoid Symptoms, angioedema). These severe reactions are related to the body's immune system response to the medicine.

Q: How quickly does Ericsone typically start working?

A: Pharmacokinetic data indicate the medicine is rapidly absorbed after oral administration. The time to reach maximum concentration (Tmax) in the bloodstream is approximately 1.6 hours.

Q: Why do some people need to adjust the timing of when they take Ericsone?

A: Official instructions mandate taking the dose after meals (post-prandial administration). This timing is generally advised to help minimize the risk of gastrointestinal side effects.

Q: Is Ericsone a controlled substance?

A: Ericsone (eperisone) is classified in the WHO ATC Index as a Centrally Acting Agent but is not typically classified as a controlled substance in the official schedules of major regulatory drug authorities.

Q: What is the difference between Ericsone and a generic version of the drug?

A: The medicine's active ingredient is eperisone hydrochloride. Generic versions contain the same active ingredient but must meet bioequivalence standards to the branded product, though they may use different inactive components.

Q: Are there any food or drink restrictions while using Ericsone?

A: Official documents mandate taking the dose after meals and specify that alcohol may enhance sedative effects. Beyond these parameters, no other specific food or drink restrictions are typically listed.

Q: What is the typical duration of Ericsone's effects after taking it?

A: Pharmacokinetic data show the drug has a short half-life of approximately 1.87 hours. The rapid elimination profile is why the medicine is typically administered multiple times per day.

Q: Is Ericsone considered a preventative medicine?

A: The general purpose of the medicine is defined as functioning as an antispasmodic agent to relieve existing muscle stiffness and tension. It is used to modulate nerve signals that cause excessive muscle contraction.

Q: What are the most common reasons Ericsone treatment is started?

A: Official documents list its use for the improvement of muscle hypertonicity symptoms associated with various conditions. These include issues like cervical spondylosis and spastic paralysis.

Q: Is Ericsone designed to be taken indefinitely?

A: Use duration is noted to vary, ranging from short courses for acute symptoms to longer-term treatment for chronic conditions like spastic paralysis. The duration is determined by the condition being managed.

Q: What is the risk of dependence or addiction described for Ericsone?

A: As a centrally acting muscle relaxant, its classification and safety profile are generally noted for a low incidence of central depression as described in official documents.

Q: Is Ericsone the first-line treatment for its approved condition?

A: Some clinical guidelines, referenced alongside regulatory data, describe eperisone as an initial treatment option for acute musculoskeletal spasm.

Q: How does Ericsone’s safety profile compare to similar medications in official summaries?

A: Comparative studies, sometimes referenced in regulatory overviews, suggest that eperisone is associated with a minimal central nervous system adverse effect profile compared to some other muscle relaxants. This relates specifically to the likelihood of side effects like heavy sedation.

How should Ericsone be stored and disposed of?

How to Store and Dispose of Ericsone

The storage and disposal instructions for Ericsone (Eperisone hydrochloride tablets) are strictly defined by regulatory documents to maintain its stability and ensure safe handling.

Official Storage Requirements

The medication must be stored at a temperature not exceeding 30°C. It is required to keep the tablets in a cool, dry, and dark place, protecting them from light and moisture. The container should be kept tightly closed to preserve the physical integrity of the tablets, especially after opening the package. The regulatory instruction to keep medicine out of reach of children is mandatory.

Official Disposal Instructions

Unused or expired Ericsone must be discarded in accordance with applicable regional, national, and local laws and regulations. It is strictly prohibited to discharge the product to sewer systems or drains to prevent environmental contamination.

Ericsone